Hospira Files an IPR Petition Challenging Genentech’s Bevacizumab Patent

On September 9, 2016, Hospira filed a petition for an IPR of U.S. Patent No. 7,622,115, owned by Genentech.  The ‘115 patent claims methods of treating various cancers with bevacizumab, which is marketed by Genentech under the brand name Avastin®.  Please see our IPR tracker page for all important IPR documents on biologic patents.